跳转到主要内容

快速连接

新闻

Sugammadex Sodium API – CADIFA Approval by ANVISA

We are glad to announce the granting of the first CADIFA ever issued by ANVISA on the 08th of September 2021, regarding the API SUGAMMADEX SODIUM, under the requirements of the Resolution – RDC nº 359/2020. This is a landmark and a moment of great happiness for us that have worked relentlessly in partnership with ANVISA and our clients at the Pharmaceutical Industry to make this achievement come true.

Contact Us

请填写以下表格,我们会尽快与您联系.

给我们发电子邮件: api@drreddys.com | +91 40 49002253